The OriGAMI-4 trial reveals subcutaneous Rybrevant's 45% response rate in metastatic head and neck cancer patients after ...
Erin Doherty, 33, chose an avant garde origami-inspired gown by Louis Vuitton, a label also favoured by Emma Stone, 37, who ...
Ten percent complete response and rapid, durable antitumor activity reported with RYBREVANT FASPRO; results surpass current standards of care RARITAN, N.J., Feb. 19 ...
Johnson & Johnson (NYSE:JNJ) today announced new results from the Phase 1b/2 OrigAMI-4 study showing that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in ...
Johnson & Johnson today announced new results from the Phase 1b/2 OrigAMI-4 study showing that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination ...
The FDA granted breakthrough therapy designation to Rybrevant Faspro based on data from the phase 1b/2 OrigAMI-4 study (NCT06385080).
Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for subcutaneous amivantamab and hyaluronidase-lpuj as ...
New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO beyond lung ...
J. Cole will play a run of massive UK arena shows later this year. The rapper recently released his huge 'The Fall-Off' album, an ambitious two-disc ...
Skoltech researchers and their colleagues from Ludwig Maximilian University of Munich, Germany, Nanjing University of China, and the National Institute for Materials Science of Japan have developed a ...
When people are dropped into the most dangerous of conditions – as when disaster strikes, or during exploration of another planet – they generally have the highest number of needs and the lowest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results